Table 1

Baseline characteristics and follow-up of 87 patients with relapsing-remitting multiple sclerosis treated with alemtuzumab

Alemtuzumab-treated patients
n87
Gender (n, % female)61 (70%)
Mean age (±SD) at first treatment in years (range)33.0 (±8)
(18–49)
Baseline EDSS, mean (±SD),
median (range)
3·8 (±1.94)
3.5 (0–8.0)
Mean annualised relapse rate over 2 years pretreatment1.78 (±0.82)
Median disease duration in months at treatment (range)36 (5–144)
Prior disease-modifying therapyn=34 (39%)
 β-interferon31 (35.6%)
 Glatiramer acetate7 (8%)
 Mitoxantrone4 (4.6%)
 Azathioprine2 (2.3%)
  • EDSS, Expanded Disability Status Scale.